Zobrazeno 1 - 10
of 50
pro vyhledávání: '"F. Mosele"'
Autor:
A. Alfaro, C. Catelain, H. El-Masri, P. Rameau, M. Lacroix-Triki, JY. Scoazec, V. Marty, F. Mosele, B. Pistilli
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Medullary carcinoma of the breast (MedBC) is a rare histological type that accounts for less than 5% of all invasive breast cancers. Here, we performed an exploratory study aimed to determine whether imaging mass cytometry (IMC) can be used
Externí odkaz:
https://doaj.org/article/e16cc33190c840d1876403ee3c5e73a3
Autor:
A. Alfaro, C. Catelain, H. El-Masri, P. Rameau, M. Lacroix-Triki, JY. Scoazec, V. Marty, F. Mosele, B. Pistilli
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/5cf3555c90bf4de39e8f9347ec79bc92
Autor:
A. Bayle, L. Belcaid, M. Aldea, D. Vasseur, F. Peyraud, C. Nicotra, A. Geraud, M. Sakkal, L. Seknazi, L. Cerbone, F. Blanc-Durand, J. Hadoux, F. Mosele, M. Tagliamento, A. Bernard-Tessier, B. Verret, C. Smolenschi, R. Clodion, N. Auger, P.M. Romano, A. Gazzah, M.N. Camus, J. Micol, O. Caron, A. Hollebecque, Y. Loriot, B. Besse, L. Lacroix, E. Rouleau, S. Ponce, J.C. Soria, F. Barlesi, F. Andre, A. Italiano
Publikováno v:
Annals of Oncology. 34:389-396
Autor:
A, Bayle, F, Peyraud, L, Belcaid, M, Brunet, M, Aldea, R, Clodion, P, Dubos, D, Vasseur, C, Nicotra, A, Geraud, M, Sakkal, L, Cerbone, F, Blanc-Durand, F, Mosele, P, Martin Romano, M, Ngo Camus, I, Soubeyran, E, Khalifa, M, Alame, L, Blouin, D, Dinart, C, Bellera, A, Hollebecque, S, Ponce, Y, Loriot, B, Besse, L, Lacroix, E, Rouleau, F, Barlesi, F, Andre, A, Italiano
Publikováno v:
Annals of Oncology. 33:1328-1331
Autor:
F. Mosele, Bojana Stefanovska, Alicia Tran-Dien, Tony Sourisseau, Fabrice Andre, Benjamin Verret
Publikováno v:
Cancer Research. 80:3062-3069
Next-generation sequencing has sparked the exploration of cancer genomes, with the aim of discovering the genetic etiology of the disease and proposing rationally designed therapeutic interventions. Driver gene alterations have been comprehensively c
Autor:
M. Campone, Bojana Stefanovska, Alexandra Jacquet, Fabrice Andre, M.P. Sablin, Hervé Bonnefoi, C. Le Tourneau, Isabelle Miran, Florence Dalenc, Cécile Jovelet, Thomas Bachelot, Amélie Lusque, F. Mosele, Nathalie Droin, A. Tran Dien, François Bertucci, Ivan Bièche, Diego Enrico, Ingrid Garberis, Jean-Charles Soria, M. Jimenez, Ludovic Lacroix
Publikováno v:
Annals of Oncology. 31:377-386
α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug famil
Autor:
Arnaud Bayle, C. Parisi, Antoine Italiano, Antoine Hollebecque, Loic Verlingue, Etienne Rouleau, Clémentine Sarkozy, S. Ponce, Pernelle Lavaud, Christophe Massard, F. Blanc-Durand, Mihaela Aldea, L. Cerbone, Y. Loriot, F. Mosele, M. Sakkal, Jean-Charles Soria, Ludovic Lacroix, D. Vasseur
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(12)
Autor:
Ian E. Krop, Nicholas C. Turner, Philippe L. Bedard, Ivan Bièche, Dejan Juric, Sibylle Loibl, Thomas Bachelot, Fatima Cardoso, Christos Sotiriou, David M. Hyman, Cristina Saura, F. Mosele, Fabrice Andre, Javier Cortes, Rosaria Condorelli, Benjamin Verret
Publikováno v:
Annals of oncology, 30 (3
Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next-generation sequencing in the context of clinical practi
Autor:
Aldo Scarpa, Albrecht Stenzinger, Nikhil Wagle, F. Mosele, S. Jezdic, A. Bayle, Fabrice Barlesi, Etienne Rouleau, Funda Meric-Bernstam, J.-Y. Douillard, Joaquin Mateo, Ivan Bièche, Julia Bonastre, Fabrice Andre, Jordi Remon, Stefan Michiels, Jorge S. Reis-Filho, Martijn P. Lolkema, Mark E. Robson, Nicola Normanno, C. B. Westphalen, R. Dienstmann
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2020, 31, pp.1491-1505. ⟨10.1016/j.annonc.2020.07.014⟩
Annals of Oncology, 31(11), 1491-1505. Elsevier Ltd.
Annals of Oncology, Elsevier, 2020, 31, pp.1491-1505. ⟨10.1016/j.annonc.2020.07.014⟩
Annals of Oncology, 31(11), 1491-1505. Elsevier Ltd.
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no recommendations from scientific societies about its use in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc8b09fd353f4a0ad4725894240a808
https://hal.archives-ouvertes.fr/hal-03493959
https://hal.archives-ouvertes.fr/hal-03493959
Autor:
Cécile Jovelet, Hervé Bonnefoi, Thomas Bachelot, M. Jimenez, J-C Soria, Alexandra Jacquet, M.P. Sablin, Isabelle Miran, M. Campone, Fabrice Andre, Nathalie Droin, François Bertucci, Ivan Bièche, C. Le Tourneau, Ludovic Lacroix, Amélie Lusque, A. Tran Dien, Florence Dalenc, F. Mosele
Publikováno v:
Annals of Oncology. 30:vii27
Background α-selective PI3K inhibitors improve PFS in patients with HR+/Her2- metastatic breast cancer (mBC) and PIK3CA mutation. Recent studies have reported that a subset of patients with PIK3CA-mutated HR+/Her2- mBC are chemoresistant. Therefore,